Michael O’Dwyer

10.2k citations

162 papers · 4.3k indexed · h-index 40

Impact in

Hematology top 0.5%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
Genetics top 1%
- Chronic Lymphocytic Leukemia Research

Papers in

Hematology 96
- Multiple Myeloma Research and Treatments 46
- Chronic Myeloid Leukemia Treatments 34
- Acute Myeloid Leukemia Research 23
Genetics 46
- Chronic Lymphocytic Leukemia Research 40

Co-authors: Brian Druker Alessandro Natoni Michael J. Mauro Ronan Swords Mark E. Gurney Afshin Samali Lokesh Joshi Paul La Rosée
Journals: Blood (48 papers)Journal of Clinical Oncology (6 papers)Leukemia (5 papers)Cancers (5 papers)Blood Advances (4 papers)
Partner nations: Ireland United States United Kingdom

In The Last Decade

Michael O’Dwyer

155 papers receiving 4.2k citations

Peers

Countries citing papers authored by Michael O’Dwyer

Since Specialization

Citations

This map shows the geographic impact of Michael O’Dwyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael O’Dwyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael O’Dwyer more than expected).

Fields of papers citing papers by Michael O’Dwyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael O’Dwyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael O’Dwyer. The network helps show where Michael O’Dwyer may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael O’Dwyer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael O’Dwyer Line = papers co-authored together Michael O’Dwyer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Protocol for isolation and expansion of natural killer cells from human peripheral blood scalable for clinical applications Biology Methods and Protocols ·Estaran Jose Manuel, E.A Calvacanti, Michael O’Dwyer, Éva Szegezdi	2025	1
2	Improving Turnaround Times for Routine Antimicrobial Sensitivity Testing Following European Committee on Antimicrobial Susceptibility Testing Methodology in Patients with Bacteraemia Antibiotics ·Richard J. Edmondson, Kordo Saeed, Gabriela Medina Garcés, Michael O’Dwyer	2024	2
3	NK cell line modified to express a potent, DR5 specific variant of TRAIL, show enhanced cytotoxicity in ovarian cancer models Heliyon ·M Garcia-Prieto, Tobias Dickmann, Ajay Prakash, Mark E. Gurney, 黄婷婷, Hannah Prendeville, Subhashis Sarkar, Joanne O’Dwyer, Michael O’Dwyer, Eimear B. Dolan	2024	2
4	Adverse effects associated with long-term use of anticholinergics amongst older adults with intellectual disability: a longitudinal cohort study International Journal of Pharmacy Practice ·Juliana Jéssica de Souza Rodrigues, Martin Henman, Philip McCallion, Mary McCarron, Michael O’Dwyer	2024	0
5	Hypersialylation and multiple myeloma SHILAP Revista de lepidopterología ·Michael O’Dwyer, Siobhán Glavey, Max Muniafu, Alessandro Natoni, Aideen E. Ryan	2024	2
6	Sialofucosylation Enables Platelet Binding to Myeloma Cells via P-Selectin and Suppresses NK Cell-Mediated Cytotoxicity Cancers ·Alessandro Natoni, AmitK Tamrakar, Maria Stefania De Propris, Maria Teresa Petrucci, Francesca Fazio, A. M. Ziegler Michael L. Hulver, Maria Laura Milani, A. Czaplicki, Robert B. Henderson, Dawn Swan, Anna Guarini, Michael O’Dwyer, Robin Foà	2023	6
7	CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment Clinical Lymphoma Myeloma & Leukemia ·Dawn Swan, Robert B. Henderson, Inga Wiehl, Schell Kh, John Quinn, Mary R. Cahill, Mavrova Heinrich, Isabelle Arm, Gokhan Cinar, Marc Nolan, Imelda Parker, Alessandro Natoni, Kevin Lynch, Aideen E. Ryan, Éva Szegezdi, Janusz Krawczyk, Philip Murphy, Michael O’Dwyer	2022	1
8	Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor–natural killer cells Cytotherapy ·Mark E. Gurney, Н. Д. Шибакова, Sarah Corcoran, Sarah Brophy, Janusz Krawczyk, Neil Otto, David Hermanson, Richard Childs, Éva Szegezdi, Michael O’Dwyer	2022	22
9	Single Cell Transcriptomics Revealed Molecular Alterations in AML Cell Clusters Relevant to Refractory Disease at Relapse Blood ·Hao Shiji, Rogerio Cury Pires, Sukhraj Pal Singh Dhami, Philippe Krebs, Michael O’Dwyer, Éva Szegezdi	2021	0
10	Patient-Initiated Discontinuation of Tyrosine Kinase Inhibitor for Chronic Myeloid Leukemia SHILAP Revista de lepidopterología ·Stephen E. Langabeer, Hideo Sawada, Michael O’Dwyer, Hasti Mohri	2020	1
11	Hypersialylation Protects Multiple Myeloma Cells from NK Cell-Mediated Immunosurveillance and This Can be Overcome By Targeted Desialylation Using a Sialyltransferase Inhibitor Blood ·J.M. Daly, Subhashis Sarkar, Alessandro Natoni, Robert B. Henderson, Dawn Swan, Mattias Carlsten, Michael O’Dwyer	2019	7
12	Targeted Approaches to Inhibit Sialylation of Multiple Myeloma in the Bone Marrow Microenvironment Frontiers in Bioengineering and Biotechnology ·Alessandro Natoni, Raghvendra A. Bohara, Abhay Pandit, Michael O’Dwyer	2019	19
13	The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma BMC Medical Research Methodology ·Susanne Schmitz, Áine Maguire, James J. Morris, Kai Ruggeri, Elisa Haller, Isla Kuhn, Ю.Н. Ахтименко, Xin-Jin Luo, LAWRANCE, Jack Bowden, 雷云杉, Michael O’Dwyer, Gordon Cook, Cathal Walsh	2018	27
14	Targeting Siglec-7: A Novel Immunotherapeutic Approach to Potentiate the Cytotoxic Functions of Natural Killer Cells Against Multiple Myeloma Blood ·J.M. Daly, Ágnes Elekes, Jinsong Hu, Alessandro Natoni, Subhashis Sarkar, A. Czaplicki, Inga Wiehl, Janusz Krawczyk, Michael O’Dwyer	2017	3
15	E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271 Leukemia ·Alessandro Natoni, Theodore A Smith, Niamh Keane, Inga Wiehl, Cathal Connolly, A. Jha, Mindaugas Andrulis, Zelmarie Besalaar, Marc S. Raab, Siobhán Glavey, A. Czaplicki, Shaji Kumar, Silvia Locatelli‐Hoops, Isabela Batista Oliva, William E. Fogler, J L Magnani, Michael O’Dwyer	2017	34
16	Targeting Selectins and Their Ligands in Cancer Frontiers in Oncology ·Alessandro Natoni, Matthew S. Macauley, Michael O’Dwyer	2016	107
17	A Cell Culture System That Mimics Chronic Lymphocytic Leukemia Cells Microenvironment for Drug Screening and Characterization Methods in molecular biology ·Alessandro Natoni, Michael O’Dwyer, Corrado Santocanale	2013	6
18	Mechanisms of Action of a Dual Cdc7/Cdk9 Kinase Inhibitor against Quiescent and Proliferating CLL Cells Molecular Cancer Therapeutics ·Alessandro Natoni, Laura S. Murillo, Lenka Novak, Mark Catherwood, Alessia Montagnoli, Afshin Samali, Michael O’Dwyer, Corrado Santocanale	2011	37
19	Targeting AML through DR4 with a novel variant of rhTRAIL Journal of Cellular and Molecular Medicine ·Éva Szegezdi, Carlos R. Reis, Almer M. van der Sloot, Alessandro Natoni, A. O’Reilly, Janice LV Reeve, Robbert H. Cool, Michael O’Dwyer, Steven Knapper, Luís Serrano, Wim J. Quax, Afshin Samali	2010	19
20	Practical Considerations for the Management of Patients in the Tyrosine Kinase Inhibitor Era Seminars in Hematology ·Michael O’Dwyer, Ehab Atallah	2009	11

About Michael O’Dwyer

Michael O’Dwyer is a scholar working on Hematology, Genetics, Immunology, Oncology and Immunology and Allergy, having authored 162 papers that have together received 4.3k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (46 papers), Chronic Lymphocytic Leukemia Research (40 papers), Chronic Myeloid Leukemia Treatments (34 papers), Immune Cell Function and Interaction (26 papers), Acute Myeloid Leukemia Research (23 papers), Glycosylation and Glycoproteins Research (18 papers), Eosinophilic Disorders and Syndromes (18 papers) and CAR-T cell therapy research (16 papers). The work is most often cited by research in Hematology (1.5k citations), Genetics (853 citations), Immunology (973 citations), Oncology (983 citations) and Rheumatology (439 citations). Michael O’Dwyer has collaborated with scholars based in Ireland, United States and United Kingdom. Frequent co-authors include Brian Druker, Alessandro Natoni, Michael J. Mauro, Ronan Swords, Mark E. Gurney, Afshin Samali, Lokesh Joshi, Paul La Rosée, Francis J. Giles and Matthew S. Macauley. Their work appears in journals such as Blood, Journal of Clinical Oncology, Leukemia, Cancers and Blood Advances.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact